Arcutis Biotherapeutics

NSQ:ARQT · US03969K1088

BiotechnologyMedium

360

Value45

Profit price54

EV / EBIT7

Price / Owner Earnings100

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price51

Price/Sales78

EV / Gross Profit64

Price/Book11

Quality62

Returns on capital72

Return on Capital69

Cash Return on Capital74

Return on Equity74

Profit margins70

EBIT Margin42

Gross Profitability98

Cash backing54

Accruals42

Owner Earnings Margin65

Growth68

Sales growth57

Profit growth96

Reinvestment79

Price momentum52

Safety34

Debt load25

Debt serviceability48

Refinancing95

Debt Payback1

Liquidity91

Sentiment45

Analyst ratings17

Expectations trend39

Opinion Changes50

Price Target Upside27

Market mood78

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Arcutis Biotherapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA

IndustryBiotechnology

SizeMedium

TypePublic Company

ExchangeNASDAQGS

Founded2016

Employees398

Websitearcutis.com

ISINUS03969K1088

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

ImmunologyInflammationDermatologyHealth DiagnosticsPharmaceutical

Description

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The company’s portfolio consists of highly differentiated to…

Analysis

Middle-of-the-road

Arcutis Biotherapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Arcutis Biotherapeutics with its peers

Forte Biosciences

NAQ:FBRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

BIOAGE Labs

NSQ:BIOA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Tyra Biosciences

NSQ:TYRA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Day One Biopharmaceuticals

NSQ:DAWN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Palvella Therapeutics

NAQ:PVLA

100

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Cytokinetics

NSQ:CYTK

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →